NCT06097455View on ClinicalTrials.gov

First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 15, 2024

Primary Completion Date

April 15, 2025

Study Completion Date

January 15, 2027

Conditions

Refractory Non-Hodgkin LymphomaRelapsed Non-Hodgkin Lymphoma

Interventions

GENETIC

ARI0003

Treatment with ARI0003 cells

Trial Locations (7)

Unknown

CHU Santiago de Compostela, Santiago de Compostela

H. Ramon y Cajal, Madrid

H.U. Virgen de la Arrixaca, Murcia

Hospital Central de Asturias, Oviedo

Hospital Son Espases, Palma de Mallorca

H. Clínico de Salamanca, Salamanca

08036

Hospital Clínic Barcelona, Barcelona

All Listed Sponsors

lead

Fundacion Clinic per a la Recerca Biomédica

OTHER

NCT06097455 - First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma | Biotech Hunter | Biotech Hunter